<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340061</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1031</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091031</ELocationID><Abstract><AbstractText>Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD patients participating in the SAFER-study, a Brazilian multicentric cohort evaluating the safety, effectiveness, and immunogenicity of SARS-CoV-2 vaccines in patients with autoimmune diseases. A descriptive analysis of the population and a binary logistic regression model were performed to evaluate the predictors of COVID-19-related hospitalization. A <i>p</i>-value &lt; 0.05 was significant. The included 160 patients were predominantly females (83.1%), with a mean (SD) age of 40.23 (13.19) years. The patients received two (19%), three (70%), or four (11%) vaccine doses. The initial two-dose series was mainly with ChAdOx1 (Oxford/AstraZeneca) (58%) or BBIBP-CorV (Sinopharm-Beijing) (34%). The first booster (n = 150) was with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (63%) or ChAdOx1 (29%). The second booster (n = 112) was with BNT162b2 (40%) or ChAdOx1 (26%). The COVID-19 hospitalization rate was 17.5%. IMRD moderate/high activity (OR: 5.84; CI: 1.9-18.5; <i>p</i> = 0.002) and treatment with corticosteroids (OR: 2.94; CI: 1.02-8.49; <i>p</i> = 0.0043) were associated with higher odds of hospitalization, while increasing the number of vaccine doses was protective (OR: 0.37; CI: 0.15-0.9; <i>p</i> = 0.032). These findings, along with previous reassuring results about the safety of the COVID-19 vaccines, argue in favor of booster vaccination in IMRD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calderaro</LastName><ForeName>Débora Cerqueira</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0001-5535-3223</Identifier><AffiliationInfo><Affiliation>Locomotor System Department, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 30130-100, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valim</LastName><ForeName>Valéria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Gilda Aparecida</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Locomotor System Department, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 30130-100, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Ketty Lysie Libardi Lira</ForeName><Initials>KLLL</Initials><AffiliationInfo><Affiliation>Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Priscila Dias Cardoso</ForeName><Initials>PDC</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Sandra Lúcia Euzébio</ForeName><Initials>SLE</Initials><AffiliationInfo><Affiliation>Escola de Medicina, Universidade Federal do Amazonas (UFAM), Manaus 69067-005, AM, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sartori</LastName><ForeName>Natalia Sarzi</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rezende</LastName><ForeName>Rodrigo Poubel Vieira</ForeName><Initials>RPV</Initials><AffiliationInfo><Affiliation>Universidade Federal Fluminense (UFF), Rio de Janeiro 24020-140, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Melo</LastName><ForeName>Ana Karla Guedes</ForeName><Initials>AKG</Initials><AffiliationInfo><Affiliation>Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba (UFPB), João Pessoa 58051-900, PB, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Vitor Alves</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade Federal de Goiás (UFG), Goiânia 74690-900, GO, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Adah Sophia Rodrigues</ForeName><Initials>ASR</Initials><Identifier Source="ORCID">0000-0002-8090-9606</Identifier><AffiliationInfo><Affiliation>Hospital Geral de Fortaleza (HGF), Universidade de Fortaleza (UNIFOR), Fortaleza 60150-160, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakehasi</LastName><ForeName>Adriana Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9411-7493</Identifier><AffiliationInfo><Affiliation>Locomotor System Department, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 30130-100, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Landa</LastName><ForeName>Aline Teixeira</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burian</LastName><ForeName>Ana Paula Neves</ForeName><Initials>APN</Initials><AffiliationInfo><Affiliation>Centro de Referências para Imunobiológicos Especiais (CRIE), Secretaria de Saúde do Estado do Espírito Santo, Vitória 29050-360, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peixoto</LastName><ForeName>Flávia Maria Matos Melo Campos</ForeName><Initials>FMMMC</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telles</LastName><ForeName>Camila Maria Paiva França</ForeName><Initials>CMPF</Initials><AffiliationInfo><Affiliation>Escola de Medicina, Universidade Federal do Amazonas (UFAM), Manaus 69067-005, AM, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>do Espírito Santo</LastName><ForeName>Rafaela Cavalheiro</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0002-5518-3479</Identifier><AffiliationInfo><Affiliation>Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Research and Innovation Science Centre, Klaipeda University, 92294 Klaipeda, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baptista</LastName><ForeName>Katia Lino</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-6134-8495</Identifier><AffiliationInfo><Affiliation>Universidade Federal Fluminense (UFF), Rio de Janeiro 24020-140, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Yasmin Gurtler Pinheiro</ForeName><Initials>YGP</Initials><AffiliationInfo><Affiliation>Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magalhães</LastName><ForeName>Vanessa de Oliveira</ForeName><Initials>VO</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima</LastName><ForeName>Raquel Lima</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Escola de Medicina, Universidade Federal do Amazonas (UFAM), Manaus 69067-005, AM, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biegelmeyer</LastName><ForeName>Erika</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4978-040X</Identifier><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorencini</LastName><ForeName>Pietra Zava</ForeName><Initials>PZ</Initials><Identifier Source="ORCID">0000-0003-2072-1705</Identifier><AffiliationInfo><Affiliation>Hospital Universitário Cassiano Antônio Moraes (HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória 29041-295, ES, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira-Carvalho</LastName><ForeName>Andréa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte 30190-002, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Reis-Neto</LastName><ForeName>Edgard Torres</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Emília Inoue</ForeName><Initials>EI</Initials><Identifier Source="ORCID">0000-0001-8540-014X</Identifier><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Marcelo de Medeiros</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-1896-8322</Identifier><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monticielo</LastName><ForeName>Odirlei André</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Viviane Angelina</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xavier</LastName><ForeName>Ricardo Machado</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0001-6570-4533</Identifier><AffiliationInfo><Affiliation>Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90010-150, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pileggi</LastName><ForeName>Gecilmara Salviato</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0003-0054-7754</Identifier><AffiliationInfo><Affiliation>Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SAFER-Study Group Task Force</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SAFER001</GrantID><Agency>Brazilian Ministry of Health</Agency><Country /></Grant><Grant><GrantID>SAFER002</GrantID><Agency>Brazilian Society of Rheumatology</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine booster shot</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">breakthrough COVID-19 infections</Keyword><Keyword MajorTopicYN="N">health disparities</Keyword><Keyword MajorTopicYN="N">rheumatic diseases</Keyword><Keyword MajorTopicYN="N">vaccination of immune compromised patients</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340061</ArticleId><ArticleId IdType="pmc">PMC11436185</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091031</ArticleId><ArticleId IdType="pii">vaccines12091031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoff L.S., Ravichandran N., Shinjo S.K., Day J., Sen P., Junior J.G., Lilleker J.B., Joshi M., Agarwal V., Kardes S., et al. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: A multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey. Rheumatol. Int. 2023;43:47–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589602</ArticleId><ArticleId IdType="pubmed">36271958</ArticleId></ArticleIdList></Reference><Reference><Citation>Isnardi C.A., Alpizar-Rodriguez D., Calderaro D.C., Marques C.D.L., Pons-Estel G.J., Xavier R.M., Saurit V., Pisoni C.N., Tissera Y.S., D’Angelo Exeni M.E., et al. Factors Associated with Mortality in Patients with Immune-Mediated Rheumatic Diseases and COVID-19 from Latin America: Data from Argentina, Mexico, and Brazil. J. Clin. Rheumatol. 2024;30:e9–e17. doi: 10.1097/RHU.0000000000002038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000002038</ArticleId><ArticleId IdType="pubmed">37936271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasseli R., Richter J.G., Hoyer B.F., Lorenz H.M., Pfeil A., Regierer A.C., Schmeiser T., Strangfeld A., Voll R.E., Krause A., et al. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. RMD Open. 2023;9:e002998. doi: 10.1136/rmdopen-2023-002998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2023-002998</ArticleId><ArticleId IdType="pmc">PMC10111193</ArticleId><ArticleId IdType="pubmed">37068915</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew J., Gianfrancesco M., Harrison C., Izadi Z., Rush S., Lawson-Tovey S., Jacobsohn L., Ja C., Hyrich K.L., Gossec L., et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: Results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open. 2022;8:e002187. doi: 10.1136/rmdopen-2021-002187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-002187</ArticleId><ArticleId IdType="pmc">PMC8987210</ArticleId><ArticleId IdType="pubmed">35387864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C., Patel N.J., D’Silva K.M., Hsu T.Y., DiIorio M., Prisco L., Martin L.W., Vanni K., Zaccardelli A., Todd D., et al. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann. Rheum. Dis. 2022;81:289–291. doi: 10.1136/annrheumdis-2021-221326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221326</ArticleId><ArticleId IdType="pmc">PMC8791428</ArticleId><ArticleId IdType="pubmed">34489304</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshukairi A.N., Al-Omari A., Albeity A., Alandijany T.A., Hassan A.M., El-Kafrawy S.A., Dada A., Al Hroub M.K., El-Saed A., Bissar L.S., et al. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination. J. Infect. Public Health. 2022;15:685–688. doi: 10.1016/j.jiph.2022.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9098803</ArticleId><ArticleId IdType="pubmed">35623243</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S., Luong Nguyen L.B., Tartour E., de Lamballerie X., Wittkop L., Loubet P., Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 2022;28:163–177. doi: 10.1016/j.cmi.2021.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.036</ArticleId><ArticleId IdType="pmc">PMC8595936</ArticleId><ArticleId IdType="pubmed">35020589</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19 Study Shows mRNA Vaccines Reduce Risk of Infection by 91 Percent for Fully Vaccinated People.  [(accessed on 28 October 2023)];2021  Available online:  https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html.</Citation></Reference><Reference><Citation>Strangfeld A., Schäfer M., Gianfrancesco M.A., Lawson-Tovey S., Liew J.W., Ljung L., Mateus E.F., Richez C., Santos M.J., Schmajuk G., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021;80:930–942. doi: 10.1136/annrheumdis-2020-219498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219498</ArticleId><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team . R: A Language and Environment for Statistical Computing [4.3.1] R Foundation for Statistical Computing; Vienna, Austria: 2023.</Citation></Reference><Reference><Citation>RStudio Team . RStudio: Integrated Development for R. RStudio, PBC; Boston, MA, USA: 2020.</Citation></Reference><Reference><Citation>Wickham H., Averick M., Bryan J., Chang W., McGowan L.D., François R., Grolemund G., Hayes A., Henry L., Hester J., et al. Welcome to the tidyverse. J. Open Source Softw. 2019;4:1686. doi: 10.21105/joss.01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoberg D.D., Whiting K., Curry M., Lavery J.A., Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13:570–580. doi: 10.32614/RJ-2021-053.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2021-053</ArticleId></ArticleIdList></Reference><Reference><Citation>Papagoras C., Fragoulis G.E., Zioga N., Simopoulou T., Deftereou K., Kalavri E., Zampeli E., Gerolymatou N., Kataxaki E., Melissaropoulos K., et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann. Rheum. Dis. 2022;81:1013–1016. doi: 10.1136/annrheumdis-2021-221539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221539</ArticleId><ArticleId IdType="pubmed">34758975</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis G.E., Karamanakos A., Arida A., Bournia V.K., Evangelatos G., Fanouriakis A., Fragiadaki K., Kravvariti E., Laskari K., Panopoulos S., et al. Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD Open. 2022;8:e002279. doi: 10.1136/rmdopen-2022-002279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002279</ArticleId><ArticleId IdType="pmc">PMC8918070</ArticleId><ArticleId IdType="pubmed">35246472</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N.J., Wang X., Fu X., Kawano Y., Cook C., Vanni K.M.M., Qian G., Banasiak E., Kowalski E., Zhang Y., et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Semin. Arthritis Rheum. 2023;58:152108. doi: 10.1016/j.semarthrit.2022.152108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152108</ArticleId><ArticleId IdType="pmc">PMC9605731</ArticleId><ArticleId IdType="pubmed">36347211</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho J.S., Dos Reis Neto E.T., Kakehasi A.M., Ribeiro S.L., Studart S.A., Martins F.P., Cavalheiro do Espírito Santo R., Ranzolin A., Fernandino D.C., Dinis V.G., et al. Factors associated with poor outcomes in SLE patients with COVID-19: Data from ReumaCoV-Brazil register. Lupus. 2023;32:42–53. doi: 10.1177/09612033221135884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221135884</ArticleId><ArticleId IdType="pmc">PMC9614598</ArticleId><ArticleId IdType="pubmed">36300790</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett R., Barrett R., Lin S.X., Culliford D., Fraser S., Edwards C.J. Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: A time series analysis (January 2019 to January 2021) using the English Prescribing Dataset. BMJ Open. 2022;12:e051936. doi: 10.1136/bmjopen-2021-051936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-051936</ArticleId><ArticleId IdType="pmc">PMC9791141</ArticleId><ArticleId IdType="pubmed">36564115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>